Dynavax Technologies Pushes for Support of Board Director Nominees Ahead of Important Annual Meeting

Dynavax's Call to Action for Stockholders

Dynavax Technologies Corporation, a leading biopharmaceutical company focused on innovative vaccine development, has taken an assertive stance ahead of its Annual Meeting of Stockholders on June 11, 2025. The company is urging its shareholders to vote "FOR" the election of its four nominated board directors—Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun—highlighting their qualifications and crucial roles in the company’s success.

Since its strategic repositioning in 2019, Dynavax has experienced notable growth and delivered significant returns to its stockholders. According to recent financial reports, the firm has generated a 203% total return over the past five years—a figure that far exceeds the returns of its vaccine peers and the broader SP Biotechnology Select Industry Index, which reported declines during the same period. This remarkable performance is rooted in the company’s effective operational execution and its disciplined capital allocation strategy.

In contrast, Dynavax’s rival, Deep Track, seeks to replace the current directors with its nominees, which Dynavax argues lack the necessary expertise in corporate strategy, operations, and finance. According to Dynavax, this potential shift threatens to undermine the company’s strategic momentum. The company emphasizes that maintaining its existing board members is vital to ensuring continued growth and protecting stockholder interests.

Protecting Long-Term Shareholder Value
Dynavax’s board members bring to the table extensive experience in biotechnology, vaccine development, and corporate finance, which is essential for navigating the complex healthcare landscape. By re-electing its current directors, Dynavax intends to sustain the progress made in enhancing stockholder value, along with driving innovative vaccine solutions to market.

Institutional Shareholder Services (ISS) and Egan-Jones, respected independent proxy advisory firms, have both endorsed Dynavax's board members, underscoring their credentials and the strategic direction they have established. ISS has pointed out the deficiencies in Deep Track’s rationale for change, noting that there hasn't been a compelling argument presented for why alterations to the board are necessary.

Dynavax responded decisively to Deep Track’s attempts to influence the election, characterizing their plan to implement a short-term strategy as detrimental. "The stripping away of our long-term growth potential for temporary results would not serve the interests of our shareholders," they assert. Furthermore, Dynavax highlights that the company’s strong position, attributed to products like the HEPLISAV-B® hepatitis B vaccine, has garnered significant market share and clinical achievements, positioning it favorably against competitors.

The Importance of Voting
As stockholders prepare for the approaching vote, Dynavax is reminding them of the importance of participating in the electoral process. Even small shareholders are encouraged to cast their votes, reinforcing that every voice matters in this critical decision-making process. The call to action includes voting on the GOLD proxy card, which represents support for the incumbent directors.

For shareholders who might face challenges in voting or need assistance, Dynavax provides resources via MacKenzie Partners, their designated proxy solicitor. Key stakeholders are reminded that time is of the essence, with the Annual Meeting set for June 11.

About Dynavax Technologies
Dynavax Technologies Corporation is dedicated to developing and commercializing vaccines aimed at preventing infectious diseases. With two notable products already on the market, including the HEPLISAV-B® vaccine, Dynavax continues to innovate in the biopharmaceutical landscape. Interested parties can learn more about their pipeline and products by visiting the company’s website.

Conclusion
In this critical juncture, Dynavax Technologies is making a clear case for existing board members to remain in their posts to sustain shareholder value and continue their trajectory of success. This meeting will not only determine the composition of the board but also signal the direction in which Dynavax aims to steer its robust growth strategy moving forward.